By Wooyoung Lee ( October 16, 2025, 06:47 GMT | Insight) -- Major South Korean pharmaceutical companies — GC Pharmaceutical, Boryung Biopharma and SK Discovery — have lost their appeal to overturn a 2023 antitrust fine imposed by the country’s competition regulator for colluding in government vaccine tenders. Other drugmakers, Korea Vaccine, Kwangdong Pharmaceutical, Yuhan Corporation, HLB, and drug distributors Wellfarm and Pharm World also failed to overturn their fines in earlier rulings this year.Major South Korean pharmaceutical companies — GC Pharmaceutical, Boryung Biopharma and SK Discovery — have lost their appeal to overturn a 2023 antitrust fine imposed by the country’s competition regulator for colluding in government vaccine tenders....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.